Heptares Therapeutics, an LMB spin-out company, announces a deal with Allergan for development of novel treatments for neurological disorders, including Alzheimer’s disease. More…
Allergan signs $3.3bn deal with Heptares
Artificial DNA could build new generation of cancer drugs
Scientists have built the first 3D nano-sized objects using artificial DNA, which could be used to deploy cancer treatments inside tumour cells. The teams from the LMB and The Institute of Cancer Research, London created microscopic pyramid- and diamond-shaped 3D ‘packets’ by folding together artificial nucleic acid building blocks called Xeno nucleic acids (XNAs). More…
Cambridge Pharmaceutical Cryo-EM Consortium
Cambridge Pharmaceutical Cryo-EM Consortium formed by FEI, five pharmaceutical companies, LMB and the University of Cambridge. Sample preparation and data collection services on a cryo-transmission electron microscope (cryo-EM) will be provided to the consortium companies for early-stage drug discovery research. More…
Mini-brains show great potential to replace animals in studying neurological disease
Madeline Lancaster has recently won the annual NC3Rs 3Rs Prize for her work on the creation of brain organoids that mimic the developing human cerebrum. More…
From Parkinson’s Disease to ubiquitin
Mechanistic studies on a few curious proteins associated with familial Parkinson’s disease have led researchers in the EMBO community, including David Komander’s group at LMB, on a journey to cast surprising new light on the universal cellular ubiquitin modification system (page 9) More…
“Sex, food and smell” Cambridge Science Festival talk @UTC_Cambridge this Sunday #csf2016
Join the LMB’s Greg Jefferis for his talk: “Sex, food and smell” at the University Technical College Cambridge, Sunday 20 March: 12:45 – 1:45pm, to learn more about the links between smell and attraction. Booking required. More…